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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not Topiramate is 
effective in the prevention of pediatric migraines.  
 
Study Design: Review of three English language randomized control trials published in 2005, 2007, 
and 2009 
 
Data sources: Three double-blind, placebo-controlled, randomized trials comparing various doses of 
Topiramate to placebo were found using PubMed, OVID, and Cochrane Library databases. 
 
Outcome(s) Measured: The frequency of migraines in patients under the age of 18 years old was 
documented with headache diaries. The patient’s parent would record the number, severity, duration, 
associated symptoms, and use of acute abortive medications  
 
Results: Three randomized, controlled studies comparing topiramate to a placebo pill were reviewed. 
The Lakshmi study found that topiramate was effective in preventing pediatric migraines. School 
absenteeism was also recorded and was found to decrease with topiramate use. The Lewis study 
illustrated statistically significant improvement in the number of migraines per month in the pediatric 
population. The Winner Study was the only RCT that revealed a reduction of migraines in the 
treatment group that was not statistically significant. The most common adverse effects of topiramate 
were weight loss, paresthesias, and anorexia.   
 
Conclusion: Topiramate is a safe and effective prophylactic medication for the prevention of 
migraines in children up to 18 years of age.  
 
Key Words: Migraines, Topiramate, Pediatric, Prevention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Zeliff, Pediatric Migraines and Topiramate, 1 
INTRODUCTION 
 Migraines are the second most common cause of headaches in the general population.1 
They can be characterized as periodic, unilateral, pulsatile headaches that usually onset in 
childhood or adolescence.  The migraine can last from 1-48 hours.2  Migraines can be triggered 
by sleep deprivation, certain foods, or irregular eating patterns. There are a variety of 
medications that have proven to be effective in treating migraines. Some people suffer from 
migraines frequently and it can affect their ability to function in everyday life.  
The exact cause of migraines is unknown. It is hypothesized that the brain is in a constant 
state of neuronal hyperexcitability and a series of neural and vascular events causes the migraine. 
One theory centers on the activation of vasoactive neuropeptides which leads to dilation of the 
blood vessels.1 Pharmacologic data concludes that neurotransmitters known as 5-
hydroxytyrptamine (5-HT; also known as serotonin) and dopamine are involved in migraines. 
Data reveals that when 5-HT receptors are activated by medication, it can abort the migraine. In 
addition, it was discovered that migraine symptoms can be induced by dopaminergic 
stimulation.1  
Headache is one of the most common complaints in pediatric medicine. Therefore, the 
Physician Assistant should be aware of its prevalence, symptoms, and treatment options. The 
medical history of the patient is pertinent to the diagnosis. The family history is positive for 
vascular, migrainous headaches in 75% of patients.2 The incidence of pediatric migraines ranges 
depending on the age of the child. Migraines affect 10.6% of children between the ages of 5 and 
15 years old and 28% of adolescents between the ages of 15-19 years old.3 Symptoms typically 
include headache, nausea, vomiting, abdominal pain, photophobia, phonophobia, vertigo, 
lightheadedness, fatigue, and changes in mood. In younger children, the headache is described as 
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bitemporal whereas in adolescents the headache is described as a unilateral, throbbing headache. 
Some may experience an aura, which can be a visual or focal disturbance such as zigzags of light 
or paresthesias. It is more common for pediatric patients to have migraines without aura. The 
International Headache Society (IHS) has proposed diagnostic criteria for the diagnosis of 
migraines. For pediatric migraines without an aura, the criteria consists of having at least 5 
attacks that have the following qualities: headache lasting 1-48 hours, headache with at least two 
of the following: bilateral/unilateral location, pulsating quality, moderate to severe intensity, and 
aggravation by routine physical activity, and during the headache, the patient must experience 
one of the following: nausea, vomiting, photophobia, or phonophobia.2 The IHS diagnostic 
criteria for migraines with aura consists of having at least two attacks with three of the following: 
one or more fully reversible aura symptoms indicating focal cortical and/or brainstem 
dysfunction, at least one aura developing gradually over more than 4 min or 2 or more symptoms 
occurring in succession, no auras lasting more than 60 min, and the headache follows in less than 
60 minutes.2 
There are many different treatment options available for migraines. Ibuprofen 10 mg/kg 
with 40-65 mg of caffeine or 65 mg of Midrin is considered the gold standard therapy to treat 
migraines in pediatric patients.2 For severe headaches that do not respond to that treatment 
option, triptans are generally used. These medications are not as effective if taken 30 minutes 
after the start of the migraine.2 In addition, they should not be used in younger children. If 
children are having recurrent migraines, one should consider preventative therapies. Prophylactic 
medications include topiramate, propranolol, amitriptyline, cyproheptadine, or valproate.4 There 
have not been many studies conducted supporting their efficacy.  
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One study determined that 329,000 school days were lost per month due to migraines.4  
Statistics from the Agency for Healthcare Research and Quality reveal that in 2009, the average 
healthcare cost for children who present to hospitals with headaches, including migraine is 
$4,607.5 The same agency revealed there were 7,699 visits to the hospital due to headaches, 
including migraines in children.5  No data was available on the cost of migraines to the patient or 
the health care system.  
This paper evaluates three double-blind, placebo-controlled, randomized trials comparing 
the efficacy of Topiramate in preventing migraines in children under the age of 18 years old. The 
mechanism of topiramate is unknown. It is hypothesized that it works by blocking the voltage-
dependant sodium channels and it potentiates an inhibitory neurotransmitter, known as GABA.6 
Topiramate is already FDA-approved for prevention of migraines in adults. There are not many 
other studies that analyzed the efficacy and safety of topiramate as a migraine prophylactic 
medication for children. 6 Topiramate is frequently used as an anti-epileptic medication. It is 
FDA approved for use in children aged 2 years or older.6 Generally, the dose of topiramate is 
larger when used as an anticonvulsant.  The maximum dose given to children is 200mg twice a 
day.6  
This method of treatment is being proposed because there are no studies supporting the 
efficacy of preventative medications for pediatric migraines. It would be more effective for a 
health care practitioner to prevent the migraine and improve the quality of life for the patient. It 
would decrease the number of office visits. In addition, it may be discovered that prophylactic 
medications are better tolerated than the abortive medications for migraines. The treatment 
medications have to be monitored   
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OBJECTIVE 
The objective of this systematic review is to determine whether or not topiramate is 
effective in preventing pediatric migraines.  
METHODS 
 Specific selection criteria of three double-blind, placebo-controlled randomized control 
trials (RCT) were used for this review. The populations of these studies were children under the 
age of 18 years old who are affected with frequent migraines. The interventions utilized in each 
RCT were various doses of Topiramate, starting at 15 mg/day up to 200mg/day orally. 
Comparisons were made between the various doses to the placebo. Outcomes measured in each 
study were based on patient oriented evidence that matters (POEMs). The outcome in each study 
was the reduction of the frequency of pediatric migraines using the International Headache 
Society (IHS) criteria.  
 Key words that were used in the searches were “Topiramate”, “migraines”, “pediatric”, 
and “prevention”. All articles were published in the English language and were published in 
peer-reviewed journals. The author researched the studies through PubMed, OVID, and the 
Cochrane Library Database. The author narrowed down the articles based on relevance and 
selected the articles based on POEMs. Inclusion criteria consisted of randomized control trials 
published after 1996 with the participants under the age of 18 years olds who met the IHS 
criteria. Exclusion criteria consisted of studies published before 1996, participants over the age 
of 18 years old, or articles with disease-oriented evidence (DOE). The statistics used in the 
studies were ANCOVA and p-values with a value <0.05 being statistically significant. 
Demographics and characteristics of the studies are presented in Table 1. 
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Table 1: Characteristics and Demographics of the Subjects 
Study Type # 
pts 
Age 
in 
years 
Inclusion Criteria Exclusion Criteria Withdrawn Interventions 
Lewis et 
al. 
(2009)3 
Double 
blind, 
parallel 
group 
RCT  
141 12-17 Patients (Pts) who 
have 3-12 migraines 
on 14 headache days 
per month; Period of 
symptoms lasted up 
to 24 hours; 
Pts who required 
preventative 
medicine but had 
previous failure; Pts 
>5th percentile in 
body weight 
Pts already on 
topiramate or 
failure of 
topiramate; Pts 
who overused 
acute meds; Pts 
with BMI 
>40kg/m2 or 
>200lb. 
38 Placebo, 
Topiramate 
50mg/day, 
Topiramate 
100 mg/day 
Lakshmi 
et al. 
(2007)7 
Double 
blind 
RCT 
44 8-14 Pts who met IHS 
criteria for migraine 
with or without aura, 
with a frequency of 
2 or more headaches 
a month for 3 
months 
Pts who had other 
types of 
headaches; Pts 
with other 
comorbid 
conditions; Pts 
who were already 
on migraine 
prophylaxis 
2 Placebo, 
Topiramate 
in various 
doses up to 
100mg/day 
Winner  
et al. 
(2005)8 
Double 
Blind 
RCT 
162 6-15 Children 6-15 who 
met the IHS criteria 
of pediatric migraine 
with or without aura 
and weighed more 
than 44 lbs. Pts 
experienced an avg 
of 3-10 migraine 
days per month. 
Females had to be 
premenarchal or on 
birth control for >1 
month prior to 
enrollment.   
Pts had cluster 
headaches, chronic 
migraine, or more 
than 15 headache 
days during the 
baseline phase. Pts 
who used 
analgesics > 12 
days per month or 
used 
ergots/triptans >8 
days per month. 
Pts who had 
previos history of 
topiramate or 
previous failure of 
>2 migraine 
preventative 
medications 
31 Placebo, 
Topiramate 
in various 
doses up to 
2.0mg/kg per 
day 
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OUTCOMES 
 In all three studies, the researchers evaluated patient oriented evidence reflecting the 
efficacy of the medication.  Headache diaries were used to record the number, severity, and 
duration of migraine headaches. Associated symptoms and use of acute abortive medications 
were also recorded.  The diaries were reviewed every 4 weeks. 
RESULTS 
 The three randomized control trials in this systematic review compared various doses of 
topiramate to placebo. The results pertaining to the primary outcomes were presented as 
continuous data in all three studies. Therefore, the continuous data could not be converted into 
dichotomous data.  
 The Lakshmi et al. study used a randomized, double-blind, placebo-controlled study to 
compare the number of migraines at baseline versus the number of migraines that occurred while 
the subject was taking topiramate over a three month maintenance period. The baseline period 
was 4 weeks long, in which the topiramate was titrated in 25mg increments per week. Forty two 
children completed the treatment per protocol. The primary outcome was measured based on the 
patient provided data in the headache diaries, which measured the frequency of the migraines. 
The results of the study revealed that there was a decrease in the mean monthly migraine 
frequency from 16.14(±9.35) at baseline to 4.27(±1.95) at the end of the study in the topiramate 
group. Alternatively, there was a smaller decrease in the mean monthly migraine frequency from 
13.38(±7.48) to 7.48(±5.94) at the end of the study in the placebo group.7 The efficacy analysis 
also revealed that the mean percentage reduction in monthly migraine frequency had a p-value of 
.02 and was deemed statistically significant. In addition, it was determined that there was a 
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greater than 50% reduction in monthly migraine days in subjects who were taking topiramate. 
Results may be seen below in Table 2. 
Table 2: Efficacy of Topiramate in the Lakshmi et al. Study 
 Topiramate 100mg (±SD) Placebo 
Mean monthly migraine 
frequency at baseline 
16.14 (±9.35) 13.38 (±7.48) 
Mean monthly migraine 
frequency after 3 month 
maintenance period 
4.27 (±1.95) 7.48 (±5.94) 
Mean percentage reduction in 
migraine frequency  
 95.2% 52.4% 
 
 The Lewis et al. study was a randomized, double-blind, placebo-controlled, parallel-
group study performed to evaluate the safety and efficacy of two dosages of topiramate as a 
preventative treatment in adolescents.  There was a pre-treatment phase that lasted up to 9 weeks, 
a double-blind phase that lasted 16 weeks, and a taper/exit phase lasting up to 6 weeks. Subjects 
who completed the pre-treatment phase and had all the entry criteria were randomly assigned to a 
50mg topiramate/day group, 100mg topiramate/day group, or a placebo group. The primary 
efficacy end point was the percent reduction in the monthly migraine frequency over the 12 week 
double-blind treatment phase. The researchers calculated the monthly migraine attack rate by 
multiplying the attack count by 28 and dividing by the number of the days in the period. The 
percent reduction was calculated using the formula: 100 X [B-D]/B, where B is the migraine 
attack rate during baseline and D is the migraine attack rate during the 12 week double-blind 
treatment period.3 The researchers stated that a positive value would indicate a reduction from 
baseline. The efficacy analysis was performed on the intention-to-treat (ITT) population, which 
included all subjects who received one or more doses of medication and provided one or more 
efficacy evaluations. The primary efficacy end point was analyzed by using an analysis of 
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covariance model (ANCOVA). Factors included age, treatment group, and analysis center 
whereas the covariate was the monthly migraine attack rate from the prospective baseline period.  
Table 3: Reduction in Monthly Migraine Attack Rate 
 Placebo Topiramate 50 mg Topiramate 100 mg 
Migraine attacks per 
month at baseline  
4.1  (±1.48) 4.1(±1.74) 4.3 (±1.59) 
Migraine attacks per 
month during 12 week 
double-blind phase 
2.4 (±1.93) 2.4 (±1.84) 1.3 (±1.23) 
Reduction in attack 
rate, % 
42.3 (±43.15) 34.1 (±55.21) 70.1 (±25.07) 
P-Value (vs. placebo)  .798 .016 
 
 The Winner et al. study is a randomized, double-blind, placebo-controlled, parallel group 
study that took place at 17 medical centers across the United States. There was a 4 week baseline 
period, followed by an 8-week titration period and a 12-week maintenance period. The study 
evaluated an intent-to-treat (ITT) population and a per-protocol population. The ITT population 
was defined as subjects who received at least one dose of medication and had at least one post-
baseline efficacy assessment. The per-protocol population consisted of all the subjects who 
completed the study without major violations. The primary efficacy analysis compared the 
reduction in the number of migraine days per month during the double-blind phase to the 
baseline phase in each treatment group of the ITT population. Subjects received topiramate for 
an average of 130 days and the average daily dose was 2.0 mg/kg per day. The analysis revealed 
that the ITT population had a decreased number of migraine days per month during the double-
blind phase. The mean change from baseline and standard deviation for the ITT population was 
2.6 (±2.6) days for the subjects on topiramate. The mean change from baseline for the placebo-
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treated subjects was 2.0 (±3.1) days. The p-value for the ITT population was .061 and was 
deemed to be approaching clinical significance. The mean change from baseline for the per-
protocol populations was 2.28 (±2.4) days for those on topiramate compared to 2.2 (±2.1) days 
for those on the placebo.8 The p-value for the per-protocol population was 0.033 and was 
deemed clinically significant. The data from the study is presented below in Table 4.  
Table 4: Reduction in monthly migraine days  
 Placebo Topiramate 
Mean change from baseline 
for the ITT population 
2.0 (±3.1) 2.6 (±2.6) 
Mean change from baseline 
for the per-protocol population 
2.2 (±2.1) 2.28 (±2.4) 
Mean monthly migraine days 
in the last 28 days of the 
double-blind phase 
3.1 (±3.0) 2.4 (±2.8)  
 
Table 5: Reduction in monthly migraine days in all three studies 
  Placebo Topiramate P-Value 
Mean change from 
baseline for the 
Lakshmi study 
13.38 (±7.48) 16.14 (±9.35) .02 
Mean change from 
baseline for the Lewis 
study 
4.1  (±1.48) 4.3 (±1.59)  .016 
Mean change from 
baseline for the per-
protocol population in 
the Winner Study 
2.2 (±2.1) 2.28 (±2.4) 0.033 
  
Each of the studies provided data on the safety of topiramate in their subjects. All three 
studies reported some mild to moderate adverse effects.  The most frequent adverse effects in the 
study by Lakshmi et al. were weight loss (81%), loss of appetite (23.8%), and paresthesias 
(23.8%).7 None of the subjects were forced to withdrawal from the study. In the Lewis et al. 
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study, the most common adverse effects reported were upper respiratory infections, paresthesia, 
and anorexia.3 Six subjects experienced treatment-emergent adverse events, such as fatigue, 
nervousness, renal calculus, and epistaxis, and withdrew from the study.  In the Winner et al. 
study, the most common adverse events reported were upper respiratory infections, anorexia, 
weight loss, paresthesias, and somnolence.8 Four subjects in the topiramate group endured severe 
adverse events, including infections, severe migraine, and suicidal ideation.  
DISCUSSION 
 This systematic review evaluated the three randomized control trials for the safety and 
efficacy of topiramate as preventative measure for children with frequent migraines. The studies 
by Lakshmi et al. and Lewis et al. both demonstrated that Topiramate was clinically significant 
in reducing the frequency of pediatric migraines. The Lewis et al. study demonstrated on average 
a 70% reduction in migraine days per month for those in the Topiramate 100mg/day group 
compared to a 34% reduction for those in the Topiramate 50mg/day group.   The Winner et al. 
study demonstrated a greater reduction in the Topiramate treatment group compared to the 
placebo group but the results were not statistically significant. The researchers hypothesized that 
the lack of statistical significance may be due to age-related fluctuations in the placebo response. 
They noticed that younger patients had a tendency to have a greater response to the placebo. 
 As mentioned previously, some children are affected by frequent migraines which can 
limit their daily activities. One of the issues addressed in the Lakshmi et al. study was school 
absenteeism. The results from this study demonstrated a decreased rate of absenteeism after 
using topiramate. The average mean at baseline was 4.04 missed school days per month and after 
treatment with Topiramate, subjects missed an average of 1.47 school days per month.7  
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 The researchers in these studies mentioned that one of the limitations in performing an 
efficacy analysis on a prophylactic medication is that it takes time for the medication to become 
effective. In this sense, the Lakshmi et al. study recommended a study that evaluated subjects for 
a longer period of time. Another limitation in the Lakshmi et al. study was the small number of 
patients enrolled.  
CONCLUSIONS 
 Topiramate is a safe and effective preventative medication for migraines in children. 
Maintaining physical function is one of the benefits of preventing the migraines in children. 
They are able to perform their daily activities and attend school. Future studies should be 
conducted to investigate the most effective dosing for the age and weight of the child. Since the 
studies focus on the pediatric population, it is important to understand the impact adverse effects 
can have on the developmental aspects of children. In addition, studies are needed to investigate 
the safety of long term use of Topiramate in children. Furthermore, there is a need to discover 
the exact mechanism of action behind migraines. Although there are medications that are 
effective in preventing and treating migraines, researchers cannot determine the exact reason 
why these medications are effective. It would be interesting if scientists could further research 
the connection between seizures, migraines, and neurotransmitters. There is a need for continued 
research on prophylactic medications for migraines in the pediatric population. It could improve 
the quality of life for these children.   
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